SCHEDULE 13G: HBM Healthcare Investments Discloses 5.1% Stake in Upstream Bio, Inc.
Beneficial Ownership Report (Schedule 13G)
HBM Healthcare Investments (Cayman) Ltd. has reported a beneficial ownership of 5.1% in Upstream Bio, Inc., holding 2,715,056 shares of common stock as of December 31, 2024.
Summary
- HBM Healthcare Investments (Cayman) Ltd. (the "Reporting Person") has filed a Schedule 13G, disclosing its beneficial ownership in Upstream Bio, Inc.
- As of December 31, 2024, the Reporting Person beneficially owns 2,715,056 shares of Upstream Bio, Inc. Common Stock.
- This ownership represents approximately 5.1% of Upstream Bio, Inc.'s outstanding Common Stock.
- The percentage is calculated based on 53,596,601 shares of Common Stock outstanding as of November 5, 2024, as reported in Upstream Bio's Form 10-Q filed on November 7, 2024.
- HBM Healthcare Investments (Cayman) Ltd. has sole voting and sole dispositive power over all 2,715,056 shares.
- The voting and investment power for HBM Healthcare Investments (Cayman) Ltd. is exercised by its board of directors, which includes Jean-Marc LeSieur, Richard H. Coles, Sophia Harris, Dr. Andreas Wicki, Mark Kronenfeld, M.D., and Richard Paul Woodhouse.
Sentiment
Score: 6
Explanation: The document is a factual disclosure of beneficial ownership. The acquisition of a significant stake by a specialized healthcare investor like HBM Healthcare Investments can be viewed as a positive signal of confidence in the issuer, hence a slightly positive sentiment.
Positives
- A significant stake (5.1%) by a specialized healthcare investor like HBM Healthcare Investments may signal confidence in Upstream Bio's long-term prospects and strategic direction.
Risks
- The document itself does not detail specific risks related to Upstream Bio's operations or financial health, as it is a beneficial ownership report.
Future Outlook
This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Upstream Bio, Inc.'s future performance or strategic outlook.
Industry Context
HBM Healthcare Investments (Cayman) Ltd. is a prominent investor in the global healthcare sector, specializing in private and public companies. Their disclosed stake in Upstream Bio, Inc., a biotechnology company, aligns with their investment focus on the healthcare industry.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially influencing market perception and confidence.
- Investment Professionals: Offers insight into institutional investment activity in Upstream Bio, Inc.
Key Dates
| Date | Description |
|---|---|
| 2024-11-05 | Date as of which 53,596,601 shares of Common Stock were outstanding, as reported in Upstream Bio's Form 10-Q. |
| 2024-11-07 | Date Upstream Bio, Inc. filed its Quarterly Report on Form 10-Q with the SEC. |
| 2024-12-31 | Date of event which requires the filing of this Schedule 13G statement (beneficial ownership stake). |
| 2025-02-13 | Date the Schedule 13G statement was signed by HBM Healthcare Investments (Cayman) Ltd. |
Keywords
Upstream Bio, HBM Healthcare Investments, Beneficial Ownership, SEC Filing, Schedule 13G, Common Stock, Healthcare Investments, Biotechnology, Institutional Investor
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.